Edwards Lifesciences CorporatioNYSE: EW
Health Care · Health Care Equipment
$89.15
+3.33%
Vol: 2.3M
Research Digest
Tuesday, June 16, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Edwards Lifesciences names Doretta Mistras new CFO effective end of May; Moody's upgrades credit rating to Baa1Neutral▶
Edwards Lifesciences announced on May 4 the appointment of Theodora 'Doretta' Mistras as CVP and CFO effective end of May 2026; she joins from Viatris where she has been CFO since March 2024. Outgoing CFO Scott Ullem steps down but stays as a strategic advisor through June 30, 2028. Moody's upgraded Edwards' credit rating to Baa1 on May 13. Shareholders approved the executive compensation package at the May 7 annual meeting. Q1 2026 revenue was $1.65B (+12.7% YoY) with EPS of $0.78 (+22% YoY), prompting raised full-year sales and EPS guidance, though shares fell 3.5% to $77.17 on May 11 on a mixed reaction. CEO Bernard Zovighian sold 36,351 shares for ~$2.83M on May 12, and CVP Donald Bobo sold shares totaling ~$1.47M on May 15.
May 20Edwards Lifesciences CEO Bernard Zovighian sold approximately $2.83 million in shares on May 12, 2026, amid CFO transition and Moody's credit rating upgrade to Baa1.Mixed▶
Edwards Lifesciences disclosed multiple insider sales this week, including CEO Zovighian's $2.83M stock sale on May 12 and CVP Donald Bobo's $1.47M sale on May 15. The company is also undergoing a CFO transition, with Theodora Mistras set to replace long-time CFO Scott Ullem at end of May. On May 13, Moody's upgraded Edwards' credit rating to Baa1, reflecting strengthening fundamentals after Q1 revenue of $1.65B (+12.7% YoY constant currency) and EPS of $0.78 (+22% YoY). The insider selling cluster creates a mixed signal versus the positive operating and credit news. Risk: continued insider selling may pressure sentiment despite raised 2026 sales outlook.
May 19Edwards Lifesciences announced new CFO appointment and received Moody's credit rating upgrade to Baa1 in May.Positive▶
Edwards announced Theodora Mistras (from Viatris) as new CFO effective end of May, replacing Scott Ullem (CFO since 2014). On May 13, 2026, Moody's upgraded Edwards' credit rating to Baa1 with stable outlook. Q1 results were strong: revenue $1.65B (+12.7% constant currency), EPS $0.78 (+22% YoY). Insider sale of 620 shares by TAVR CVP on May 18. Analysts: Barclays raised PT to $110 (Overweight), Bernstein to $96, TD Cowen reiterated Buy at $97. Bear case: CFO transition risk and high TAVR competition.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Edwards Lifesciences appointed Doretta Mistras as CFO effective end of May; CEO sold $2.83M in shares on May 12.Mixed▶
Edwards Lifesciences announced the appointment of Theodora ("Doretta") Mistras as CFO effective end of May, joining from Viatris where she served as CFO since March 2024. CEO Bernard Zovighian sold 36,351 shares for $2.83M on May 12. Q1 2026 results showed revenue of $1.65B (+12.7% YoY constant currency) and EPS of $0.78 (+22% YoY), beating estimates. The company issued 2026 guidance of $6.5B-$6.9B in full-year sales and Q2 sales of $1.66B-$1.74B. Shares fell 3.5% to $77.17 on May 11 despite Q1 beat. The company presented at the BofA Global Healthcare Conference on May 12. Risk: divergent investor views on long-term growth trajectory and TAVR competitive dynamics.
May 14Edwards Lifesciences names Doretta Mistras new CFO effective end of May while CEO Zovighian sells $2.83M in sharesMixed▶
Edwards Lifesciences announced the appointment of Theodora 'Doretta' Mistras (previously CFO of Viatris) as corporate VP and CFO effective at the end of May 2026, succeeding Scott Ullem. On May 12, CEO Bernard Zovighian sold 36,351 shares for approximately $2.83 million, and also presented at the BofA Securities 2026 Health Care Conference. The company reported strong Q1 2026 results with revenue of $1.65B (+12.7% YoY constant currency) and EPS of $0.78 (+22% YoY), beating estimates. Edwards issued Q2 sales guidance of $1.66B-$1.74B and full-year guidance of $6.5B-$6.9B. Wall Street has 10 Buy ratings and zero Sell ratings on the stock. Shares traded between $78.29 and $81.36 on May 13.
May 13Edwards Lifesciences names new CFO and CEO sells $2.83M in shares amid strong Q1 momentumPositive▶
On May 12, 2026, Edwards Lifesciences announced the appointment of Theodora 'Doretta' Mistras as corporate VP and CFO effective end of May, joining from Viatris where she served as CFO since March 2024. The same day, CEO Bernard Zovighian sold 36,351 shares totaling approximately $2.83 million. Edwards participated in the BofA Securities 2026 Health Care Conference May 12 with a fireside chat at 3:40 p.m. PT. The news comes on the heels of Q1 2026 results showing 12.7% constant-currency revenue growth to $1.65 billion and 22% YoY EPS growth to $0.78, surpassing both analyst estimates and company guidance. Following strong results, TD Cowen reiterated Buy with a $97 price target and Bernstein SocGen raised its target to $96.
May 12Edwards Lifesciences Q1 revenue +12.7% to $1.65B, EPS +22%; raises 2026 outlook; new CFO appointedPositive▶
Edwards Lifesciences reported Q1 2026 revenue of $1.65 billion (up 12.7% YoY) and EPS of $0.78 (up 22%), and raised its 2026 sales growth outlook. The company named Theodora Mistras as new CFO effective end of May, succeeding Scott Ullem (CFO since 2014). Analyst sentiment is positive: TD Cowen reiterated Buy with a $97 PT; Stifel maintained Buy at $110; Bernstein SocGen raised PT to $96; Barclays raised to $110. Growth is driven by TAVR franchise expansion and TMTT product traction. Shares closed at $79.96 on May 8, up 6.9% over 52 weeks.
May 11Edwards Lifesciences names Viatris veteran Doretta Mistras as new CFO effective end of May ahead of BofA Healthcare ConferencePositive▶
Edwards Lifesciences announced the appointment of Theodora (Doretta) Mistras as corporate VP and CFO effective at the end of May 2026. Mistras joins from Viatris where she served as CFO since March 2024, bringing prior experience from healthcare investment banking at Citigroup and Goldman Sachs. The company will present at the BofA Securities 2026 Health Care Conference on May 12. Edwards also announced 10-year results from the Commence aortic trial, reinforcing the long-term durability of its proprietary devices. Q1 2026 net sales rose to $1.65 billion with EPS of $0.66, driven by TAVR and TMTT growth. Full-year sales guidance is $6.5-$6.9 billion. TD Cowen maintained a Buy rating with $97 price target. A VP sold 1,019 shares in insider activity.
May 8Edwards Lifesciences Q1 beats, appoints new CFO amid growth momentumPositive▶
Edwards Lifesciences reported Q1 2026 revenue of $1.65B (+16.7% YoY), slightly above $1.64B estimate, driving stock appreciation. Company guided 2026 revenue of $6.4–$6.8B (+8%–10% growth) with adjusted EPS of $2.80–$2.95. TAVR, TMTT, and Surgical segments all tracking well with TMTT targeting $2B by 2030. Company appointed Theodora "Doretta" Mistras as CFO effective end of May, replacing Scott Ullem. Mistras joins from Viatris where she was CFO since March 2024, bringing strong global finance leadership. Analyst consensus is "Buy" with 12-month price target of $96.37 (+15.7% upside). Stock momentum supported by structural heart therapy adoption and strong TAM expansion in TMTT category.
May 7Edwards Lifesciences appoints Doretta Mistras as new CFO effective May 29; reports strong TAVR growth in Q1Positive▶
Edwards Lifesciences announced Theodora (Doretta) Mistras will become CFO effective May 29, succeeding Scott Ullem. Mistras joins from Viatris where she was CFO since March 2024; previously held senior roles at Citigroup and Goldman Sachs healthcare investment banking. Company reported strong Q1 FY26 with 13.3% Q4 2025 sales growth to $1.57B and full-year 2025 sales up 11.5%. FY26 guidance: $6.4-6.8B sales (8-10% growth) and adjusted EPS $2.80-2.95. 21 analysts rate Buy with $96.37 PT (15.7% upside).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| EWEDWARDS | $89.15 | +3.33% | +4.7% | 25.6x | 0.87 | $49.7B |
| ABTABBOTT | $89.97 | +1.47% | +0.9% | 14.6x | 0.62 | $154.4B |
| ISRGINTUITIVE | $420.56 | +0.96% | -5.3% | 35.3x | 1.45 | $147.5B |
| SYKSTRYKER | $308.58 | +0.21% | -1.7% | 18.4x | 0.79 | $118.1B |
| MDTMEDTRONIC | $80.93 | +0.68% | +4.0% | 12.6x | 0.60 | $103.2B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.